ESMO Advanced Course on Immunotherapy in Lung Cancer: a new Paradigm with unanswered Questions

Programme

ZURICH SWITZERLAND

3-4 JULY 2019

Co-Chairs
John B.A.G. Haanen, NL
Aurélien Marabelle, FR
ESMO ADVANCED COURSE ON
LUNG CANCER IN IMMUNOTHERAPY:
A NEW PARADIGM WITH UNANSWERED QUESTIONS
Zürich, Switzerland
3-4 July 2019

CO-CHAIRS: John B.A.G. Haanen, Netherlands
Aurélien Marabelle, France

SPEAKERS: Maurice Párol, France
Solange Peters, Switzerland
David Planchard, France

LEARNING OBJECTIVES
- Understanding the key players in tumour immunology
- Getting up-to-date on the role of immunotherapy in advanced Non-Small-Cell Lung Cancer (NSCLC)
- Understanding the role of biomarkers in selecting NSCLC patients for IT
- Why should angiogenesis inhibition be combined with Check-Point Inhibitors
- How to manage IT toxicity and how to use IT in specific subgroups of patients

ACCREDITATION
The programme of this event has been accredited with 10 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further information please refer to www.esmo.org.

ACKNOWLEDGEMENTS
This event is supported by an unrestricted educational grant from

AstraZeneca, MSD

ORGANISATION AND CONTACTS
ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org
Welcome and introduction
John B.A.G. Haanen, NL

What every medical oncologist should know about Tumour Immunology
30’
John B.A.G. Haanen, NL
5’
Discussion

Session 1
30’
State-of-the-art: Immunotherapy with Immune Check-Point Inhibitors of Locally Advanced and Metastatic Non-Small-Cell Lung Cancer in first and later-lines
Maurice Pérol, FR
5’
Discussion

Coffee break

Session 2
20’
Are all fit patients’ candidates for first-line treatment with Immune Check-Point Inhibitors?
Debate Pro: one size fits all!
Maurice Pérol, FR
5’
Discussion

Debate Contra: Patients should be selected based on predictive biomarkers
20’
David Planchard, FR
5’
Discussion

Session 3
20’
In TPS-50%, what is best in first-line: single agent Pembrolizumab or CT-IO combination?
Solangé Peters, CH
5’
Discussion

Questions and Answers

Lunch

Session 4
20’
What is the rational for adding anti-angiogenics to Immune Check-Point Inhibitors?
Solangé Peters, CH
5’
Discussion

Session 5
20’
Refining patient selection: Immuno-score, -profiling, -gram and Tumour Mutation Burden
The point of view of the Immunologist
John B.A.G. Haanen, NL
5’
Discussion

Session 6
20’
Efficacy evaluation of Immune Check-Point Inhibitors: RECIST 1.1, iRECIST or irRECIST?
The issue and risk of hyper-progression
Brain metastasis as a target
Aurélien Marabelle, FR
5’
Discussion

Questions and Answers

Coffee break
15:20-15:45  Session 7  
20’  Toxicity issues with Immune Check-Point Inhibitors  
John B.A.G. Haanen, NL  
5’  Discussion  
15:45-16:10  Use of Check-Point Inhibitors in patients with AID and chronic viral infections  
20’  Aurelién Marabelle, FR  
5’  Discussion  
16:10-16:30  Questions and Answers  
19:00  Networking dinner

Thursday, 4 July 2019

09:00-12:30  Workshop sessions  
Three parallel workshop sessions with approx. 20 delegates in each group (delegates will attend all 3 sessions on a rotation basis)  
15’ Introduction based on clinical cases presented by speakers  
35’ Discussion  
10’ Break  

Workshop 1  When to stop immunotherapy or treatment beyond progression  
Aurelién Marabelle, FR  

Workshop 2  Choosing treatment based on biomarkers  
David Planchard, FR  

Workshop 3  Managing toxicity  
John B.A.G. Haanen, NL  

11:00-11:30  Coffee break  

11:30-12:30  Workshops 1-2-3 continuation  

12:30-13:15  Feedback on the workshops from each group  

13:15-13:30  Synthesis and wrap-up  
John B.A.G. Haanen, NL  
Aurelién Marabelle, FR  

13:30-14:30  Lunch